| A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors (NCT05502393) | Shanghai Junshi Bioscience Co., Ltd. | 2022-07-26 |
| A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (NCT05389462) | ADC Therapeutics S.A. | 2022-07-13 |
| A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (NCT05338346) | Antengene Discovery Limited | 2022-07-08 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors (NCT05818917) | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 2022-07-07 |
| Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection (NCT05378737) | Bio-Thera Solutions | 2022-07-06 |
| A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors (NCT05688605) | Shanghai Miracogen Inc. | 2022-06-30 |
| A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers (NCT05349409) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-06-09 |
| A Study of KL340399 in Patients With Advanced Solid Tumors (NCT05387928) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-06-07 |
| A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors (NCT05393063) | Akeso | 2022-06-01 |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (NCT05379985) | Revolution Medicines, Inc. | 2022-05-31 |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS (NCT05277168) | Jiangsu HengRui Medicine Co., Ltd. | 2022-05-30 |
| Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors (NCT05234853) | Purinomia Biotech, Inc. | 2022-04-28 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416) | Blueprint Medicines Corporation | 2022-04-07 |
| Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors (NCT05153096) | NovaRock Biotherapeutics, Ltd | 2022-04-01 |
| Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (NCT05164458) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-22 |
| A Study of SKB315 in Patients With Advanced Solid Tumors (NCT05367635) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-03-16 |
| Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms (NCT05287165) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2022-03-10 |
| A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (NCT05172856) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma (NCT05275062) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2022-02-15 |
| A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors (NCT05254665) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-02-01 |
| TT-702 in Patients With Advanced Solid Tumours. (NCT05272709) | Cancer Research UK | 2022-01-19 |
| A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors (NCT05114915) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-01-07 |
| A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (NCT05114759) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-01-04 |
| Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors (NCT05194709) | Wuxi People's Hospital | 2021-12-30 |
| A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors (NCT05125523) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-28 |
| Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China (NCT05105971) | Bio-Thera Solutions | 2021-12-23 |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283) | Merck Sharp & Dohme LLC | 2021-12-17 |
| A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors (NCT05134948) | Bristol-Myers Squibb | 2021-11-30 |
| A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (NCT05109975) | Debiopharm International SA | 2021-11-05 |
| Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (NCT05768321) | GenEros Biopharma Hangzhou Ltd | 2021-11-04 |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (NCT05083481) | Astellas Pharma Global Development, Inc. | 2021-10-19 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab (NCT05029882) | AbbVie | 2021-10-13 |
| Study of INCA 0186 in Subjects With Advanced Solid Tumors (NCT04989387) | Incyte Corporation | 2021-10-04 |
| A Study of SKLB1028 in Patients With Advanced Solid Tumor (NCT05072522) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-01 |
| A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors (NCT06172309) | Nanjing Chia-tai Tianqing Pharmaceutical | 2021-09-24 |
| A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors (NCT05116891) | Cantargia AB | 2021-09-22 |
| The Safety and Efficacy of Multiple-dose of WJ01024 in Subject With Advanced Cancer (NCT04991129) | Suzhou Junjing BioSciences Co., Ltd. | 2021-09-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (NCT04972981) | ADC Therapeutics S.A. | 2021-09-09 |
| Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors (NCT05862831) | Biotheus Inc. | 2021-09-07 |
| A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (NCT05010525) | Shanghai Antengene Corporation Limited | 2021-09-01 |
| A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults (NCT04999202) | Bayer | 2021-08-30 |
| A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors (NCT05240898) | Hoffmann-La Roche | 2021-08-26 |
| A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors (NCT05017623) | Eucure (Beijing) Biopharma Co., Ltd | 2021-08-26 |
| IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors (NCT05972460) | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 2021-08-18 |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors (NCT04943900) | Bristol-Myers Squibb | 2021-08-09 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors (NCT04921878) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-30 |
| Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors (NCT05537987) | InnoCare Pharma Inc. | 2021-07-30 |
| Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (NCT04830501) | TransThera Sciences (Nanjing), Inc. | 2021-07-12 |
| A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors (NCT04911881) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-24 |
| A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors (NCT04911894) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-21 |
| Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors (NCT04856774) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2021-06-01 |
| A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer (NCT04492488) | Shanghai Miracogen Inc. | 2021-05-24 |
| First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) (NCT04882917) | EMD Serono Research & Development Institute, Inc. | 2021-05-24 |
| A Study of Q-1802 in Patients With Advanced Solid Tumors (NCT04856150) | QureBio Ltd. | 2021-05-21 |
| The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere (NCT04811118) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-05-18 |
| Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (NCT04808362) | Peptomyc S.L. | 2021-04-28 |
| A Study of GC101 TIL in Advanced Solid Tumors (TR) (NCT04967833) | Shanghai Juncell Therapeutics | 2021-04-22 |
| Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (NCT05865925) | Luye Pharma Group Ltd. | 2021-04-22 |
| Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors (NCT04716634) | BeiGene | 2021-04-19 |
| First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors (NCT04746612) | Haihe Biopharma Co., Ltd. | 2021-04-08 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors (NCT04747470) | Gilead Sciences | 2021-03-25 |
| A Study of EMB-02 in Participants With Advanced Solid Tumors (NCT04618393) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-03-11 |
| Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. (NCT04778839) | First Affiliated Hospital of Zhejiang University | 2021-03-04 |
| The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (NCT04768868) | Impact Therapeutics, Inc. | 2021-02-25 |
| Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules (NCT04675060) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-02-23 |
| A Study of ICP-192 in Patients With Advanced Solid Tumors (NCT04565275) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-02-01 |
| A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors (NCT04699929) | Eucure (Beijing) Biopharma Co., Ltd | 2021-01-26 |
| A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors (NCT05171790) | Qilu Pharmaceutical Co., Ltd. | 2021-01-11 |
| A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors (NCT04659096) | Ionis Pharmaceuticals, Inc. | 2021-01-05 |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors (NCT04672460) | Pfizer | 2020-12-21 |
| Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel (NCT04471675) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2020-12-02 |
| A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2618 Injection in Subjects With Advanced Solid Tumors (NCT04623892) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-12-01 |
| Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors (NCT05905614) | Shanghai Pharmaceuticals Holding Co., Ltd | 2020-11-03 |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors (NCT04222413) | National Cancer Institute (NCI) | 2020-10-27 |
| Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (NCT04487236) | Suzhou Zanrong Pharma Limited | 2020-10-15 |
| Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (NCT03993678) | Swiss Cancer Institute | 2020-10-12 |
| Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors (NCT05063318) | PharmaMar | 2020-10-07 |
| The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors (NCT05731934) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2020-09-15 |
| Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (NCT04362748) | Amgen | 2020-09-15 |
| A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors (NCT04446260) | Jiangsu HengRui Medicine Co., Ltd. | 2020-09-07 |
| A Study of KC1036 in Patients with Advanced Solid Tumors (NCT04387916) | Beijing Konruns Pharmaceutical Co., Ltd. | 2020-09-04 |
| A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors (NCT04481009) | Eucure (Beijing) Biopharma Co., Ltd | 2020-08-04 |
| FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors (NCT04699643) | EverNov Medicines (Zhuhai Hengqin) Co., Ltd | 2020-07-30 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874) | Genentech, Inc. | 2020-07-29 |
| A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors (NCT04393298) | UCB Biopharma SRL | 2020-07-09 |
| Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors (NCT04450901) | Y Biologics Inc. | 2020-07-01 |
| A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets (NCT04408079) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-06-25 |
| Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors (NCT05731752) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2020-05-28 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors (NCT04309968) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2020-04-07 |
| Study of AMG 650 in Adult Participants With Advanced Solid Tumors (NCT04293094) | Volastra Therapeutics, Inc. | 2020-03-11 |
| The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors (NCT04312282) | Odonate Therapeutics, Inc. | 2020-03-06 |
| IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (NCT04261075) | MedImmune LLC | 2020-03-03 |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 (NCT04144140) | Eisai Inc. | 2020-02-24 |
| Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors (NCT04126590) | Changchun Intellicrown Pharmaceutical Co. LTD | 2020-01-09 |
| Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors (NCT04169672) | Hutchison Medipharma Limited | 2019-12-26 |
| Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors (NCT04172454) | Akeso | 2019-12-20 |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (NCT04185883) | Amgen | 2019-12-17 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors (NCT04214093) | AstraZeneca | 2019-12-16 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |